Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab plus Pembrolizumab in Advanced NSCLC (Lung-MAP S1800A)
NCT03971474Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- May 2019
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ramucirumab, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by SWOG Cancer Research Network. Started May 2019; status: completed.
02
Drugs
ramucirumabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03971474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971474.